Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

agitation

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

Biogen Idec building

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Study reveals two copies of APOE4 gene could increase risk of developing Alzheimer’s

The progressive neurodegenerative disease is the most common form of dementia

- PMLiVE

Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

AD is the most common form of dementia, which affects around 55 million people globally

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

- PMLiVE

Study reveals early menopause and higher CVD risk could be linked to cognitive decline

Approximately 733,040 people in Canada are estimated to be living with dementia

- PMLiVE

Two UK clinical trials launched to identify blood tests for dementia diagnosis

The neurodegenerative condition affects more than 944,000 people in the UK

- PMLiVE

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Research Partnership

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links